PEKOS, PETER — Insider Profile

Insider Profile

PEKOS, PETER

🔒 Follow — get an alert on any new filing

$CRDL

Companies Filed At

Open-Market Buys (2yr)

$50K

Buy Value (2yr, open-market)

Jun 30, 2026

Most Recent Trade

Credibility
Score

Hit Rate

-18.8%

Avg 90d Return

-11.9%

Median 90d Return

Evaluated Trades

-0.3%

Best Trade

-51.8%

Worst Trade

Hit rate and returns are based on 7 open-market buys with evaluable 90-day outcomes. Score reflects historical conviction, not a guarantee of future performance. Limited signal — either below-average timing or insufficient trade history.

Cross-Company Track Record

67%

Hit Rate · 90d

+10.9%

Median Alpha · 90d

Closed Buys Evaluated

67%

Beat XIU

All-insider base rate: 59% hit rate · +1.3% mean alpha (n=11504)

cluster buyer size concentrated

Entry: closing price on SEDI filing date (point-in-time). Exit: 90 calendar days later. Alpha vs XIU.TO (iShares TSX 60). Closed trades only. Not investment advice.

Research 3 closed buys with individual return outcomes available on the Research plan.

Date	Company	Role	Nature	Dir.	Shares	Price	Value	Score
Jun 30, 2026	$CRDL Cardiol Therapeutics Inc	—	Comp. Grant	Buy	30,000	—	—	45
Dec 30, 2025	$CRDL Cardiol Therapeutics Inc	—	Comp. Grant	Buy	15,594	—	—	45
Dec 03, 2025	$CRDL Cardiol Therapeutics Inc	—	Comp. Grant	Buy	60,000	$1.40	$84K	45
Sep 30, 2025	$CRDL Cardiol Therapeutics Inc	—	Comp. Grant	Buy	14,318	—	—	45
Dec 17, 2024	$CRDL Cardiol Therapeutics Inc	—	Open Market	Buy	38,750	$1.29	$50K	45
Jul 10, 2024	$CRDL Cardiol Therapeutics Inc	—	Comp. Grant	Buy	100,000	—	—	45
Sep 30, 2022	$CRDL Cardiol Therapeutics Inc	—	Comp. Grant	Buy	68,157	$1.41	$96K	45
Sep 30, 2022	$CRDL Cardiol Therapeutics Inc	—	Comp. Grant	Buy	68,157	$1.41	$96K	45
Sep 30, 2022	$CRDL Cardiol Therapeutics Inc	—	Expiry	Sell	60,000	$5.00	$300K	45
Jun 04, 2020	$CRDL Cardiol Therapeutics Inc	—	Open Market	Buy	20,000	$0.22	$4K	45
Jun 04, 2020	$CRDL Cardiol Therapeutics Inc	—	Open Market	Buy	40,000	$2.39	$96K	45

Muted rows are plan purchases, compensation grants, or DRIP — not open-market. Confluence Scores reflect the company's current score, not the score at time of trade.